Olema Pharmaceuticals (OLMA) early Monday said the US Food and Drug Administration has cleared the investigational new drug application for the company's OP-3136 drug candidate to treat breast and other types of cancer.
The company is expecting to begin phase 1 testing of OP-3136 early in 2025, Olema said.
Price: 10.51, Change: +0.06, Percent Change: +0.57
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。